|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,500,000 |
Market
Cap: |
2.01(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.65 - $65 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,000 |
384,322 |
579,546 |
794,601 |
Total Sell Value |
$42,551 |
$21,525,712 |
$32,066,990 |
$40,646,784 |
Total People Sold |
1 |
4 |
8 |
10 |
Total Sell Transactions |
2 |
10 |
25 |
62 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Zasloff Michael A |
Director |
|
2017-06-01 |
4 |
S |
$17.01 |
$255,201 |
D/D |
(15,000) |
32,411 |
|
- |
|
Zasloff Michael A |
Director |
|
2017-06-01 |
4 |
OE |
$10.77 |
$161,550 |
D/D |
15,000 |
47,411 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2017-05-31 |
4 |
S |
$17.26 |
$63,070 |
D/D |
(3,654) |
237,688 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2017-05-30 |
4 |
S |
$16.76 |
$131,230 |
D/D |
(7,828) |
241,342 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2017-05-30 |
4 |
S |
$16.93 |
$72,731 |
D/D |
(4,297) |
86,522 |
|
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2017-05-23 |
4 |
OE |
$11.51 |
$3,047,882 |
I/I |
264,895 |
1,058,705 |
|
- |
|
Luo Mary Z. |
COO,Chief Scientist & Chairman |
|
2017-05-23 |
4 |
OE |
$11.51 |
$4,400,447 |
D/D |
382,448 |
1,554,950 |
|
- |
|
Prins Richard K |
Director |
|
2017-05-11 |
4 |
S |
$15.43 |
$115,725 |
D/D |
(7,500) |
23,000 |
|
- |
|
Prins Richard K |
Director |
|
2017-05-11 |
4 |
OE |
$10.77 |
$80,775 |
D/D |
7,500 |
30,500 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2017-04-21 |
4 |
D |
$14.74 |
$20,400 |
D/D |
(1,384) |
90,819 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2017-04-14 |
4 |
D |
$14.80 |
$11,159 |
D/D |
(754) |
34,494 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2017-03-27 |
4 |
D |
$14.27 |
$84,735 |
D/D |
(5,938) |
249,170 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist Chairman |
|
2017-03-27 |
4 |
D |
$14.27 |
$132,297 |
I/I |
(9,271) |
793,810 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist Chairman |
|
2017-03-27 |
4 |
D |
$14.27 |
$392,140 |
D/D |
(27,480) |
1,172,502 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2017-03-26 |
4 |
D |
$13.76 |
$7,816 |
D/D |
(568) |
46,972 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2017-03-26 |
4 |
D |
$13.76 |
$8,449 |
D/D |
(614) |
35,248 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2017-03-26 |
4 |
D |
$13.76 |
$25,084 |
D/D |
(1,823) |
92,203 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2017-03-26 |
4 |
D |
$13.76 |
$64,865 |
D/D |
(4,714) |
255,108 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist Chairman |
|
2017-03-26 |
4 |
D |
$13.76 |
$92,247 |
I/I |
(6,704) |
803,081 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist Chairman |
|
2017-03-26 |
4 |
D |
$13.76 |
$299,954 |
D/D |
(21,799) |
1,199,982 |
|
- |
|
Zhou Rong |
EVP, Production Center |
|
2017-03-17 |
4 |
D |
$13.75 |
$17,160 |
D/D |
(1,248) |
47,540 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2017-03-17 |
4 |
D |
$13.75 |
$50,930 |
D/D |
(3,704) |
94,026 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2017-03-17 |
4 |
D |
$13.75 |
$16,418 |
D/D |
(1,194) |
35,862 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2017-03-17 |
4 |
D |
$13.75 |
$96,924 |
D/D |
(7,049) |
259,822 |
|
- |
|
Luo Mary Z. |
COO, Chief Scientist, Chairman |
|
2017-03-17 |
4 |
D |
$13.75 |
$136,826 |
I/I |
(9,951) |
809,785 |
|
- |
|
956 Records found
|
|
Page 28 of 39 |
|
|